FindTrial
Sign In

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00663286
Enrollment
1399
Registered
2008-04-22
Start date
2006-10-31
Completion date
Unknown
Last updated
2008-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.

Interventions

DRUGIDP-110

Topical application for 12 weeks

DRUGClindamycin

Topical application for 12 weeks

DRUGBenzoyl peroxide

Topical application for 12 weeks

DRUGVehicle

Topical application for 12 weeks

Sponsors

Dow Pharmaceutical Sciences
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

* Dermatological conditions of the face other than acne that could interfere with clinical evaluations * Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Design outcomes

Primary

MeasureTime frame
Change from baseline in number of lesions12 weeks

Secondary

MeasureTime frame
Change from baseline in global severity12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026